Recent News

• 05.07.2025 - Q1 2025 Charles River Laboratories International, Inc. Earnings Conference Call
• 04.22.2025 - Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development
• 04.15.2025 - Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call
• 03.25.2025 - Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform
• 03.12.2025 - Charles River Laboratories at the Barclays 27th Annual Global Healthcare Conference
• 03.11.2025 - Charles River Laboratories to Present at Barclays Global Healthcare Conference
• 02.25.2025 - Charles River Announces Agreement with Singapore General Hospital
• 02.19.2025 - Q4 2024 Charles River Laboratories International, Inc. Earnings Conference Call
• 02.19.2025 - Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance

Recent Filings

• 04.17.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.02.2025 - ARS Annual Report to Security Holders
• 04.02.2025 - DEF 14A Other definitive proxy statements
• 02.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.21.2025 - 8-K Current report
• 02.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.20.2025 - 144 Report of proposed sale of securities
• 02.19.2025 - 8-K Current report